Dyne Therapeutics, Inc. (DYN) stock
DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.02−0.68 (-4.07%)
Close on Nov 17, 2026Market cap $2.99BP/E –Yield –
Dyne Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Dyne Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$536.96M. For fiscal 2025 it was -$468.18M. The highest annual figure on record is -$13.83M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$468.18M | – |
| FY2024 | Dec 31, 2024 | -$343.89M | – |
| FY2023 | Dec 31, 2023 | -$242.16M | – |
| FY2022 | Dec 31, 2022 | -$170.96M | – |
| FY2021 | Dec 31, 2021 | -$150.03M | – |
| FY2020 | Dec 31, 2020 | -$58.65M | – |
| FY2019 | Dec 31, 2019 | -$13.83M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$181.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$125.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$116.13M | – |
| Q3 FY2025 | Sep 30, 2025 | -$113.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$115.79M | – |
| Q1 FY2025 | Mar 31, 2025 | -$122.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$97.11M | – |
| Q3 FY2024 | Sep 30, 2024 | -$105.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$71.96M | – |
| Q1 FY2024 | Mar 31, 2024 | -$69.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$67.69M | – |
| Q3 FY2023 | Sep 30, 2023 | -$62.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.74M | – |
| Q1 FY2023 | Mar 31, 2023 | -$45.46M | – |
| Q4 FY2022 | Dec 31, 2022 | -$40.15M | – |
| Q3 FY2022 | Sep 30, 2022 | -$42.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -$52.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$35.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$42.77M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$25.13M | – |
| Q4 FY2020 | Dec 31, 2020 | -$28.60M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.52M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.68M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.85M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.47M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.63M | – |
See a number that looks wrong?